NOVOCURE LTD's ticker is NVCR and the CUSIP is G6674U108. A total of 313 filers reported holding NOVOCURE LTD in Q4 2022. The put-call ratio across all filers is 1.54 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,294 | -67.1% | 80,150 | -15.4% | 0.01% | -65.8% |
| Q2 2023 | $3,934 | -31.0% | 94,789 | 0.0% | 0.04% | -33.3% |
| Q1 2023 | $5,700 | -15.3% | 94,789 | +3.3% | 0.06% | -19.7% |
| Q4 2022 | $6,733 | -99.9% | 91,789 | 0.0% | 0.07% | -13.4% |
| Q3 2022 | $6,974,000 | -8.3% | 91,789 | 0.0% | 0.08% | +10.8% |
| Q1 2022 | $7,605,000 | +10.4% | 91,789 | 0.0% | 0.07% | +21.3% |
| Q4 2021 | $6,891,000 | -35.4% | 91,789 | 0.0% | 0.06% | -38.4% |
| Q3 2021 | $10,664,000 | -47.6% | 91,789 | 0.0% | 0.10% | -47.1% |
| Q2 2021 | $20,360,000 | +62.8% | 91,789 | -3.0% | 0.19% | +52.0% |
| Q1 2021 | $12,505,000 | -22.1% | 94,609 | +1.9% | 0.12% | -23.6% |
| Q4 2020 | $16,060,000 | +62.6% | 92,809 | +4.6% | 0.16% | +43.8% |
| Q3 2020 | $9,874,000 | +79.6% | 88,709 | -4.3% | 0.11% | +72.3% |
| Q2 2020 | $5,498,000 | -11.9% | 92,709 | 0.0% | 0.06% | -26.1% |
| Q1 2020 | $6,243,000 | – | 92,709 | – | 0.09% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Invus Financial Advisors, LLC | 350,884 | $26,344,000 | 8.01% |
| HARTLINE INVESTMENT CORP/ | 318,109 | $23,884,000 | 3.27% |
| Deep Track Capital, LP | 550,000 | $41,294,000 | 2.92% |
| MORGAN JESS S & CO INC | 43,975 | $3,302,000 | 2.03% |
| Taylor Frigon Capital Management LLC | 46,376 | $3,482,000 | 1.09% |
| Darsana Capital Partners LP | 258,937 | $19,441,000 | 0.90% |
| Private Harbour Investment Management & Counsel, LLC | 13,562 | $1,018,000 | 0.81% |
| Rhenman & Partners Asset Management AB | 120,387 | $9,610,000 | 0.64% |
| COURAGE CAPITAL MANAGEMENT LLC | 10,000 | $751,000 | 0.50% |
| Baillie Gifford | 9,615,168 | $721,906,000 | 0.40% |